Login to Your Account

Other News To Note

Wednesday, December 21, 2011
• Apeiron Biologics AG, of Vienna, Australia, said GlaxoSmithKline plc, of London, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01), has initiated a Phase IIa study in patients suffering from acute lung injury.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription